Nitroglycerin topical - MediQuest

Drug Profile

Nitroglycerin topical - MediQuest

Alternative Names: MQX-503; Vascana

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediQuest Therapeutics
  • Class Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Raynaud's disease

Most Recent Events

  • 01 Dec 2016 Covis completes a phase II trial in Raynaud's disease in USA (NCT02688270)
  • 22 Feb 2016 Covis Pharma plans a phase II trial for Raynaud's disease in USA (Topical) (NCT02688270)
  • 16 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top